BPC-157, or Body Protection Compound-157, is a synthetic peptide derived from a protein found in human gastric juice. It's become one of the most discussed compounds in the peptide wellness community — and for good reason. The research, while still largely preclinical, is remarkably consistent.
Evidence Summary — BPC-157
| Compound | Evidence Tier | Key Studies | FDA Status | Safety Notes |
|---|---|---|---|---|
| BPC-157 (systemic / injectable) | Tier C | Sikiric 2018 (review); Chang 1997 (original isolation) | No FDA-approved formulation; removed from compounding (REMS) 2023; not legal as a research chemical for human use in US | No long-term human safety data; preclinical safety profile is favorable; no human LD50 established |
| BPC-157 (oral form) | Tier C | Sikiric 2013 (GI healing, rodents); one completed human pilot (unpublished as of 2026) | No FDA approval; oral BPC-157 studied in one completed Phase II trial (Pliva/Sikiric group); results pending | No serious adverse events reported in human pilot; GI tolerance appears good; systemic safety unstudied in humans |
Tier C = preclinical/animal data only; no published human RCTs. See our evidence grading standards.
What is BPC-157?
BPC-157 is a 15-amino-acid peptide fragment. It doesn't exist in nature in this exact form — it's a stable fragment of a larger protein called BPC (Body Protection Compound) that your stomach naturally produces. Researchers created this synthetic version because it's more stable and easier to study.
The "body protection" name isn't marketing — it comes from the peptide's observed effects on tissue repair across multiple organ systems in animal studies.
What the Research Shows
Free Resource
Get the free Peptide Starter Guide
BPC-157, Semaglutide, TB-500, GHK-Cu, Thymosin Alpha-1 — what the research says and how to source safely. Straight to your inbox.
🔒 No spam. Unsubscribe anytime.
The majority of BPC-157 research comes from animal models, primarily conducted by Dr. Predrag Sikiric's lab in Zagreb, Croatia. While human clinical trials are limited, the breadth and consistency of the animal data is notable:
- Gut healing: Multiple studies show accelerated healing of gastric ulcers, inflammatory bowel damage, and esophageal lesions
- Tendon and ligament repair: Studies demonstrate faster healing of Achilles tendon injuries, with improved collagen organization
- Muscle healing: Accelerated recovery from muscle crush injuries and cuts in animal models
- Neuroprotection: Some evidence of protection against brain injuries and promotion of nerve regeneration
- Anti-inflammatory effects: Consistent reduction in inflammatory markers across multiple tissue types
How It Works
The exact mechanism isn't fully mapped, but researchers have identified several pathways:
BPC-157 appears to upregulate growth hormone receptors, promote angiogenesis (new blood vessel formation), and modulate the nitric oxide system. It also interacts with the dopamine and serotonin systems, which may explain some of its reported effects on mood and gut function — the gut-brain axis connection.
One particularly interesting finding: BPC-157 seems to counteract the damage caused by NSAIDs (like ibuprofen) on the gut lining, which is significant given how widely these drugs are used. Similar protective effects have been observed against ethanol-induced gastric lesions — making BPC-157 a mechanistically interesting complement to glutathione support in alcohol recovery protocols. For the overlapping science, see our guide to glutathione and hangover recovery.
What We Don't Know Yet
Honesty matters here. There are real gaps in the evidence:
- Limited human trials: Most data comes from rats and mice. Animal results don't always translate to humans
- Long-term safety: No long-term safety studies exist in humans
- Optimal dosing: Without human trials, dosing protocols are extrapolated from animal data
- Drug interactions: Essentially unstudied in combination with other medications
- Regulatory status: BPC-157 is not FDA-approved for any medical condition
Clinical vs. Anecdotal Evidence: What’s the Difference?
Most BPC-157 discussion online conflates preclinical rodent studies with human clinical outcomes. Here’s how to read the evidence clearly:
| Claimed Benefit | Evidence Type | Strength | Key Source |
|---|---|---|---|
| Gastric ulcer / gut mucosal healing | Rodent + rat RCTs; one human pilot | Strongest | Sikiric 2013 |
| Tendon & ligament repair | Rodent studies only | Moderate (animal) | Krivic 2006 |
| Muscle injury recovery | Rodent crush-injury models | Moderate (animal) | Novinscak 2008 |
| Neuroprotection | Rodent brain-injury models | Early (animal) | Tudor 2014 |
| Systemic anti-inflammatory | Animal only; mechanism studies | Preclinical only | Multiple Sikiric lab publications |
FDA Regulatory Status & Legal Classification
BPC-157 occupies an unusual regulatory position. Here’s what you need to know as of 2026:
- Not FDA-approved for any indication. No approved drug product exists.
- Removed from 503A/503B compounding lists: In 2023, the FDA removed BPC-157 from the list of bulk drug substances that can be used in compounding pharmacies. This means US-licensed compounding pharmacies can no longer legally produce it. Clinicians who previously prescribed it through compounders have had to discontinue or find alternative sourcing.
- Research use only: BPC-157 is available as a research chemical for laboratory use, but human administration outside a licensed clinical trial is not authorized.
- International status varies: BPC-157 is not scheduled as a controlled substance in most countries, but it is not approved as a pharmaceutical anywhere globally. Some countries permit import for personal use — check your local regulations.
- One completed human trial: The Sikiric group completed a Phase II trial for inflammatory bowel disease (oral BPC-157). Results had not been published in a peer-reviewed journal as of early 2026. FDA IND status for BPC-157 has not been publicly confirmed for other indications.
Key Takeaways
BPC-157 has a compelling preclinical research profile, particularly for gut health and tissue repair. The consistency of results across dozens of animal studies is noteworthy. However, the lack of human clinical trials means we're working with incomplete information.
If you're considering BPC-157, the responsible approach is to work with a healthcare provider who understands peptides and can monitor your response. This is not a supplement you pick up casually — it's a research compound that deserves informed decision-making.
Frequently Asked Questions
Is BPC-157 legal in the United States? +
BPC-157 is not FDA-approved for any use. In 2023, the FDA removed it from the list of bulk substances permitted for use in compounding pharmacies (503A/503B). This means US compounders can no longer legally produce it. It remains available as a “research chemical” for laboratory use, but human administration outside a licensed clinical trial is not authorized under US law. Internationally, status varies — it is not a scheduled controlled substance in most countries but is also not approved as a pharmaceutical anywhere globally.
Why are there so few human trials on BPC-157? +
Most BPC-157 research originated from one lab group (Dr. Predrag Sikiric, University of Zagreb) using rodent models. Human clinical trials require significantly more funding, regulatory clearance, and institutional support than animal studies. The Sikiric group did complete one Phase II human trial for inflammatory bowel disease using oral BPC-157, but results were not published in a peer-reviewed journal as of early 2026. Pharmaceutical companies have limited commercial incentive to develop a naturally-occurring peptide they cannot patent in its basic form, which further constrains human trial investment.
What is the difference between injectable and oral BPC-157? +
Injectable BPC-157 (subcutaneous or intramuscular) delivers the peptide systemically, allowing it to reach musculoskeletal, neural, and systemic targets. Most animal research on non-GI effects (tendon repair, neuroprotection) used injections. Oral BPC-157 is more relevant for gut-specific effects — it may act locally in the GI tract without significant systemic absorption. Some animal studies suggest oral administration still produces systemic effects, but the bioavailability mechanism is not fully understood. The completed human trial (Sikiric group, IBD) used the oral form.
Does BPC-157 promote tumor growth? +
Angiogenesis (new blood vessel formation) — a known BPC-157 mechanism — theoretically could support tumor growth, since tumors require vascular supply. This concern is reasonable and worth taking seriously. However, the available animal data does not show tumor promotion; some preclinical models actually suggest anti-tumor effects in specific contexts. The honest answer is: we don’t know in humans. Without long-term human safety trials, this risk cannot be quantified. Individuals with a personal or family history of cancer should discuss this with an oncologist before considering BPC-157.
What does the research say about BPC-157 for gut healing? +
Gut healing is the best-supported indication for BPC-157. Multiple rodent studies show accelerated healing of gastric ulcers, esophageal lesions, and inflammatory bowel damage. The mechanism involves upregulation of growth factors (EGF, VEGF), improved mucosal blood flow, and anti-inflammatory signaling in GI tissue. BPC-157 also appears to counteract NSAID-induced gut damage in animal models — a relevant finding given widespread NSAID use. The completed human Phase II IBD trial used oral BPC-157 for this indication. Results pending peer review.
- The Tripeptide Your Liver Begs For After a Night Out — Glutathione & Hangover Recovery
- BPC-157 + KPV: The Gut-Healing Peptide Stack
- GHK-Cu: The Copper Peptide Complete Guide
- TB-500: What the Research Says About Thymosin Beta-4
- The Complete Guide to Peptide Stacking: What You Can (and Can't) Combine
- Are Peptides Legal Again? What the FDA Reclassification Actually Means
